The association between preoperative CEA, the systemic inflammatory response and survival in colon cancer.

Authors

null

Allan Matthew Golder

Academic Unit of Surgery, Glasgow, United Kingdom

Allan Matthew Golder , James Hugh Park , David Mansouri , Paul G. Horgan , Donald C. McMillan , Campbell SD Roxburgh

Organizations

Academic Unit of Surgery, Glasgow, United Kingdom, University of Glasgow, Glasgow, United Kingdom, Department of Surgery, University of Glasgow, Glasgow, United Kingdom, University of Glasgow, Glasgow, NY, United Kingdom

Research Funding

No funding received

Background: Prior to curative surgery for colon cancer, carcinoembryonic antigen (CEA) has been reported to be a poor prognostic factor recommended for routine measurement, however the majority of studies evaluating this have not adjusted for the preoperative systemic inflammatory response (SIR) –widely shown to be associated with worse outcomes. The present study aims to analyse the association between preoperative CEA and long-term outcomes when adjusted for other factors including Systemic Inflammatory Grade (SIG). Methods: The effect on overall/cancer specific survival (OS/CSS) of preoperative CEA (<5/5+) was examined in a regional cohort of patients undergoing surgery for colon cancer after adjustment for other clinicopathological factors including the SIR as measured by Systemic Inflammatory Grade (SIG). Results: 624 patients were identified undergoing curative surgery for colon cancer with a preoperative CEA available. For 3-year OS stratified by TNM Stage, CEA offered further prognostic value in patients with TNM Stage I (98% vs 75%, p=0.002), but not Stage II (p=0.444) or Stage III (p=0.351) disease. For 3-year OS stratified by SIG, CEA did not add further significant prognostic value for any SIG (all p>0.05). On multivariate analysis, age (HR 1.65, p=0.020), sex (HR 0.53, p=0.001), mode of presentation (HR 1.93, p=0.008), TNM Stage (HR 1.83, p<0.001) and SIG (HR 1.30, p<0.001) remained significant for OS, but not CEA (p=0.620). Conclusions: The present results show that there is limited prognostic value of preoperative CEA. The SIR as measured by SIG should be routinely measured prior to curative colonic surgery. A mandatory reporting dataset is required in colorectal cancer and should include SIG.

Overall and cancer specific survival stratified by clinicopathological variables including preoperative CEA (uni and multivariate analysis).

Variable
Cancer Specific Survival (CSS)
Overall Survival (OS)
UVA
MVA
UVA
MVA
HR

(95% CI)
P
HR

(95% CI)
P
HR

(95% CI)
P
HR

(95% CI)
P
Age
1.43

(1.13-1.82)
0.003
1.38

(1.05-1.80)
0.020
1.65

(1.35-2.01)
<0.001
1.65

(1.30-2.09)
<0.001
Sex
0.77

(0.53-1.12)
0.170
-
-
0.68

(0.50-0.92)
0.012
0.53

(0.37-0.76)
0.001
SIMD
0.85

(0.74-0.97)
0.014
-
0.096
0.86

(0.77-0.95)
0.004
-
0.069
Mode of presentation
2.27

(1.36-3.81)
0.002
-
0.226
2.30

(1.52-3.50)
<0.001
1.93

(1.18-3.14)
0.008
Smoking
1.04

(0.78-1.37)
0.799
-
-
1.22

(0.98-1.52)
0.076
-
0.093
TNM
3.19

(2.29-4.43)
<0.001
2.65

(1.74-4.05)
<0.001
2.07

(1.64-2.61)
<0.001
1.83

(1.39-2.42)
<0.001
EMVI
3.78

(2.51-5.67)
<0.001
2.24

(1.38-3.65)
0.001
2.38

(1.76-3.23)
<0.001
-
0.272
Differentiation
1.50

(0.98-2.30)
0.062
-
0.957
1.52

(1.08-2.15)
0.017
-
0.219
SIG
1.51

(1.29-1.75)
<0.001
1.39

(1.19-1.63)
<0.001
1.45

(1.29-1.64)
<0.001
1.30

(1.13-1.49)
<0.001
Preop anaemia
1.20

(0.94-1.53)
0.135
-
-
1.42

(1.18-1.71)
<0.001
-
0.987
CEA
1.61

(1.18-2.18)
0.002
-
0.812
1.86

(1.28-2.70)
0.001
-
0.620

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Diagnostics

DOI

10.1200/JCO.2022.40.4_suppl.027

Abstract #

27

Poster Bd #

B3

Abstract Disclosures

Similar Abstracts

First Author: Allan Matthew Golder

Abstract

2020 Gastrointestinal Cancers Symposium

Clinical utility of the systemic inflammatory response (SIR) in identifying high-risk stage II colon cancer.

First Author: Allan Matthew Golder

First Author: Allan Matthew Golder

First Author: JEONGSEOK JEON